



COVID-19 Provider Update

Wednesday, March 23, 2022

Age coverage: Specific age groups

Reported to CT WiZ by 3/15/2022

			At least one dose		Fully vaccinated		Additional dose received	
Age Range	% of Population	CT Population	Number	%	Number	%	Number	%
<5	5.00%	181,710	0	0.00%	0	0.00%	0	0.00%
5-11	8.00%	277,630	131,876	47.5%	112,728	40.6%	583	0.2%
12-15	5.00%	176,600	142,856	80.9%	130,134	73.7%	39,492	22.4%
16-17	3.00%	91,500	80,234	87.7%	73,213	80.0%	30,462	33.3%
18-24	10.00%	342,073	289,229	84.6%	240,667	70.4%	97,981	28.6%
25-34	13.00%	448,029	399,294	89.1%	344,660	76.9%	142,110	31.7%
35-44	12.00%	427,141	399,583	93.5%	354,677	83.0%	174,483	40.8%
45-54	13.00%	476,905	431,780	90.5%	394,468	82.7%	225,917	47.4%
55-64	14.00%	513,455	505,120	98.4%	466,160	90.8%	307,286	59.8%
65-74	10.00%	352,819	368,250	100.0%	337,582	95.7%	254,791	72.2%
75-84	5.00%	186,095	192,096	100.0%	175,460	94.3%	132,177	71.0%
85+	3.00%	91,330	80,132	87.7%	72,457	79.3%	48,368	53.0%
Grand Total		3,565,287	3,020,450	84.7%	2,702,206	75.8%	1,453,650	40.8%

At least one dose includes individuals who have received one dose of Pfizer, Moderna, or J&J

Fully vaccinated includes individuals who received one dose of J&J, two doses of an mRNA vaccine (Pfizer or Moderna)

Additional dose received includes individuals who have had at least one dose after completion of the primary COVID-19 vaccine series (mRNA or J & J)

Total excludes 421 people with unknown age

Age coverage: Everyone over a certain age

Data reported to CT Wiz by 3/15/2022

			At least one dose		Fully vaccinated		Additional dose Received	
Age Range	% of Population	CT Population	Number	%	Number	%	Number	%
All ages	100.00%	3,565,287	3,020,871	84.7%	2,702,536	75.8%	1,453,759	40.8%
5+	95.00%	3,383,577	3,020,450	89.3%	2,702,206	79.9%	1,453,650	43.0%
12+	87.00%	3,105,947	2,888,574	93.0%	2,589,478	83.4%	1,453,067	46.8%
16+	82.00%	2,929,347	2,745,718	93.7%	2,459,344	84.0%	1,413,575	48.3%
18+	80.00%	2,837,847	2,665,484	93.9%	2,386,131	84.1%	1,383,113	48.7%
35+	57.00%	2,047,745	1,976,961	96.5%	1,800,804	87.9%	1,143,022	55.8%
45+	45.00%	1,620,604	1,577,378	97.3%	1,446,127	89.2%	968,539	59.8%
55+	32.00%	1,143,699	1,145,598	100.0%	1,051,659	92.0%	742,622	64.9%
65+	18.00%	630,244	640,478	100.0%	585,499	92.9%	435,336	69.1%
75+	8.00%	277,425	272,228	98.1%	247,917	89.4%	180,545	65.1%


At least one dose includes individuals who have received one dose of Pfizer, Moderna, or J&J

Fully vaccinated includes individuals who received one dose of J&J, two doses of an mRNA vaccine (Pfizer or Moderna)

Additional dose received includes individuals who have had at least one dose after completion of the primary COVID-19 vaccine series (mRNA or J & J)




Percent with at least one dose of COVID-19 vaccine by Race / Ethnicity and Age Group

Data reported to CT Wiz by 3/15/2022



Percent with an additional dose of COVID-19 vaccine by Race / Ethnicity and Age Group

Data reported to CT Wiz by 3/15/2022



Race — Hispanic — NH Black — NH White

Bulletin Updates

Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults

- Tuesday, March 15, 2022, Pfizer [applied](#) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose for adults 65 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.

Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its Covid-19 Vaccine in the U.S.

- Thursday, March 17, 2022, Moderna [applied](#) to the FDA for EUA of an additional booster dose for adults 18 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.

FDA's VRBPAC is [scheduled to meet April 6, 2022](#), to discuss considerations for use of COVID-19 vaccine booster doses and the process for COVID-19 vaccine strain selection to address current and emerging variants.

No decisions regarding approval have been made, nor have there been any changes to the current [ACIP recommendations](#). Please continue to administer all COVID-19 vaccines according to the recommended schedule.

Programmatic Updates

CoVP Bulletin

Per the bulletin distributed on Wednesday, 3/16/22, we will no longer send out weekly bulletins to CoVP providers. Instead, we will plan and distribute communications when there are relevant updates to share. Thanks for your continued commitment to reviewing our communications and sharing with your staff.

CoVP Update Cadence

Beginning Wednesday, April 6th, we will conduct the CoVP Provider Update calls once per month. These call will fall on the first Wednesday of the month. See the dates of the next two calls below:

- April 6, 2022
- May 4, 2022

CDC Morbidity and Mortality Weekly Report



Stay informed about COVID-19

Read the latest
reports from
MMWR



bit.ly/MMWR_COVID19

MMWR

- COVID-19—Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status — COVID-NET, 14 States, July 2021–January 2022. Link [here](#).
- Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022. Link [here](#).
- COVID-19 Vaccine Provider Access and Vaccination Coverage Among Children Aged 5–11 Years — United States, November 2021–January 2022. Link [here](#).
- SARS-CoV-2 Incidence in K–12 School Districts with Mask-Required Versus Mask-Optional Policies — Arkansas, August–October 2021. Link [here](#).
- Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022. Link [here](#).

CDC Morbidity and Mortality Weekly Report



COVID-19 mRNA vaccines help protect against the most serious COVID-19 outcomes, even during Omicron*


Adults who received 3 doses of a COVID-19 vaccine were **94% less likely** to be put on a ventilator or die from COVID-19 compared with adults who were not vaccinated

Stay up to date with COVID-19 vaccines

* Among adults aged 18 years and older hospitalized at 21 U.S. medical centers during March 11, 2021–January 24, 2022

bit.ly/MMWR7112e1


 



Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022

CDC Morbidity and Mortality Weekly Report

During the peak of Omicron, COVID-19 hospitalization rates in Black adults were **nearly 4x** as high as rates among White adults*



Improving access to and confidence in vaccinations is needed to reduce this disparity

* Weekly COVID-19-associated hospitalization rates among adults aged ≥18 years – COVID-NET, 14 States

bit.ly/MMWR7112e2



MMWR

Unvaccinated adults and those vaccinated with a primary series, but no booster or additional dose, were 12 and three times as likely to be hospitalized, respectively, as were adults who received booster or additional doses.

COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status — COVID-NET, 14 States, July 2021–January 2022



CT WiZ/VAMS Update

VaccineFinder Update

Version 1.0
3/22/2022

VaccineFinder Reminder

- We appreciate your efforts in continuing to update inventory information daily in [VaccineFinder](#).
- CDC and the White House have notified us that future vaccine orders may not be distributed without up-to-date inventory reporting from CoVP providers via VaccineFinder.
- **In order to avoid any supply delays, any providers who are not enrolled in VaccineFinder must enroll ASAP.**
- Providers who are already enrolled in VaccineFinder must report inventory through the portal daily, in addition to any CT WiZ reporting.
 - Note: CT WiZ and VaccineFinder are two separate requirements of the CoVP enrollment.
- [VaccineFinder Provider Resources](#)

VaccineFinder Help

If you have any questions regarding issues/updating your VaccineFinder account, please submit a [help desk ticket](#) to DPH (see next slide).

This may include:

- ✓ Updating your overall contact for VaccineFinder
- ✓ Updating your address to be displayed
- ✓ Change in office hours
- ✓ Updating primary/backup vaccine coordinator

If you need the registration email resent, or have issues logging in your account, please contact the CDC VaccineFinder Helpdesk:

- ✓ Available M-F, 8am – 8pm
- ✓ Email: CARS_HelpDesk@cdc.gov
- ✓ Phone: 1-833-748-1979



VaccineFinder
is now an
option in DPH
Helpdesk
ticketing
system!

Create a ticket

* - Required Field

**What system do you need
assistance with?**

Immunizations (CT WiZ) ▼

*

Select the category:

Clinic Administration ▼

*

Select the topic:

Vaccine Finder issues/updates ▼

*

Select the sub topic:

Select a sub topic... ▼

First name of the submitter:

*

Last name of the submitter:

*

Question and Answers

To ask a question, please raise your hand using the hand icon on your screen, type your question in the chat box or if you are on the phone press *6 to unmute yourself.

If you have additional questions after the meeting, please feel free to email them to DPH.Immunizations@ct.gov

You can fill out a help desk ticket by visiting <https://dph-cthelpdesk.ct.gov/Ticket>